Last reviewed · How we verify
NCT03547141
Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers
Phase 1 trial testing MBA-P01 in Healthy in 28 participants. Completed in 1 November 2018.
28 August 2018
Quick facts
| Lead sponsor | Medy-Tox |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 28 |
| Start date | 16 April 2018 |
| Primary completion | 28 August 2018 |
| Estimated completion | 1 November 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Medy-Tox — full company profile →
Who can join
Adults 20 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the pharmacodynamic and safety of MBA-P01 in Healthy Male Volunteers
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03547141
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MBA-P01
Trials testing the same drug.
- NCT05321979 — Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines · Phase 3 · completed
- NCT05059587 — Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines · Phase 3 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Medy-Tox trials
Trials by the same sponsor.
- NCT05195112 — Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 3 · completed
- NCT04157686 — MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) · Phase 3 · completed
- NCT04281745 — Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® · Phase 4 · unknown
- NCT04144049 — A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat · Phase 2 · completed
- NCT04143854 — Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03547141 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medy-Tox
- Last refreshed: 26 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03547141.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing